Drugs / Tetanus Vaccine, Adsorbed
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06123663 | Dec 2023 → Jan 2024 | tetanus | CanSino Biologics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus Vaccine, Adsorbed | “Tetanus Vaccine, Adsorbed (TTVA)” NCT06123663 ↗ |
| Known as | TTVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06123663 ↗ |
| Modality | Vaccine | “Adsorbed Tetanus Vaccine” NCT06123663 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT06123663 ↗ |